Panelists discuss how recent advancements in treatment strategies for ALK-positive and BRAF-positive V600E NSCLC, including efficacy updates and the management of brain metastases, can enhance personalized care and optimize patient outcomes.
October 25th 2024
Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
November 1st 2024
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.
November 8th 2024
Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.
Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.
November 15th 2024
Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.
Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
November 22nd 2024
Panelists discuss the role of immunotherapy in the treatment landscape for BRAF-positive NSCLC, considering factors influencing the choice between immunotherapy and targeted therapy, emerging therapies, ongoing clinical trials, and approaches to dosing, sequencing, and toxicity management for both ALK and BRAF inhibitors.
Panelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.